Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

Overview of attention for article published in New England Journal of Medicine, August 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 12 news outlets
blogs: 2 blogs
twitter: 266 X users
patent: 1 patent
facebook: 12 Facebook pages
wikipedia: 3 Wikipedia pages

googleplus: 3 Google+ users
reddit: 3 Redditors
f1000: 1 research highlight platform
guideline: 5 clinical guideline sources
bluesky: 2 Bluesky users

Readers on

mendeley: 571 Mendeley
citeulike: 2 CiteULike

So far, Altmetric has seen 325 X posts from 266 X users, with an upper bound of 2,933,476 followers.

@JohnKastelein @JoshJwageman @Drlipid @lipo_fan @PeterJAnderson_ @ethanjweiss @DrScottMurray @ApoDudz @ianriddockmd @DrIngold @theproof @NutritionMadeS3 This REVEAL? “There were no significant between-group differences in the risk of death, cancer, or ot…

@ZKForTre @drjasonfung Also https://t.co/8dykFBYyhz

Referanslar👇 https://t.co/xYvbkPz5kl https://t.co/wADUmHRg15

@Nick_Ant_Twit @ethanjweiss Torcetrapib increased events. But anacetrapib decreased them. You have to squint real hard. Merck decided it wasn't worth commercializing. https://t.co/6c8SDeaIEc

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 321 additional X posts.

Login to access the Sentiment Analysis related to this output.